Protects against contracting diarrhoea



When the risk of contracting diarrhoea is high,  LACTOGG® may be taken to reduce the chance of getting infected. Clinical studies have shown GG probiotic's effectiveness in the following circumstances:

  1. Reduces the chance of contracting gastroenteritis in children
  2. Reduces the chance of coming down with traveller’s diarrhea

 

The following table lists a selection of professional bodies and medical societies which recommend the use of the GG probiotic in their guidelines.




Besides instituting good standards of hygiene, LACTOGG® can be taken immediately by everyone at home whenever one family member contracts diarrhoea to reduce the chance of gastroenteritis spreading within the family.

This also applies if there is an outbreak of acute diarrhoea in playschools and nurseries.

LACTOGG® is especially useful during festivities and holidays when travelling, eating out and interaction with crowds are common.
 

How should LACTOGG® be taken?

Babies, children and adults:
1 sachet or 1 capsule a day until the risk of being infected is over.

Travellers:
1 sachet or 1 capsule a day, started at least 3 days before the date of travel and continued until return from travel.




References:

Gunaydin G et al. Engineered Lactobacillus rhamnosus GG expressing IgG-binding domains of protein G: Capture of hyperimmune bovine colostrum antibodies and protection against diarrhea in a mouse pup rotavirus infection model. Vaccine 2014;32:470-477

Maragkoudakis PA et al. Lactic acid bacteria efficiently protect human and animal intestinal epithelial and immune cells from enteric virus infection. Int J Food Microbiol 2010;141(S):S91-S97

Marianelli C et al. Evaluation of antimicrobial activity of probiotic bacteria against Salmonella enterica subsp. enterica serovar Typhimurium 1344 in a common medium under different environmental conditions. Res Microbiol 2010;161(8):673-680

Roselli M et al. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr 2006;95:1171-84

Sindhu KNC et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: A randomized, double-blind, Placebo controlled trial. Clin Infect Dis 2014;58(8):1107-15

Wu S et al. Probiotic Lactobacillus rhamnosus GG mono-association suppresses human rotavirus-induced autophagy in the gnotobiotic piglet intestine. Gut Pathog 2013;5(1):22

Zhang Z et al.Protective effects of Lactobacillus rhamnosus GG against human rotavirus-induced diarrhoea in a neonatal mouse model.Pathog Dis 2013;67(3):184-191 







Hong Kong Special Administrative Region PaediHealth (HK) Ltd. (1286528) 18th Floor, United Centre, 95 Queensway
Hong Kong
Tel: +852 3486 7233     Fax: +852 3486 3723
China Guangzhou Synthgensys Biotechnology Co. Ltd. Unit 501-1, No. 7, Spiral 4 Road, Guangzhou International Bioisland, P R China Tel: +0757 26616888     Fax: +0757 26382288 Brunei Am Prolife Company (P20017787) P.O. Box 31, Jalan Gadong
BE3919, Brunei Darulssalam
Tel: +673 7335566
Email: amprolifebn@gmail.com
Singapore ProbioCare Pte. Ltd. (201603757R) 32 Ean Kiam Place
Singapore 429119
Tel: +65 6255 5592     Fax: +65 6255 5563
Malaysia ProbioCare Sdn. Bhd. (1124987-P) 122 Jalan Ipoh
51200 Kuala Lumpur
Malaysia Tel: +603 2011 1223     Fax: +603 2094 7723

Thailand Paedicare (Thailand) Co. Ltd 973 President Tower, Level 14
Unit D and E (1423) Ploenchit Road, Lumpini,
Pathumwan, Bangkok 10330, Thailand
Tel: +66 99 2828338
FOLLOW US websiteusers@lactogg.com Brochures Privacy Policy Glossary
Copyright 2017-2022 Guangzhou Synthgensys Biotechnology Co.Ltd.